- CIMERLI™ is the only biosimilar approved for all five Lucentis® indications
- Commercially available in 0.3 mg and 0.5 mg dosages
- U.S. commercial launch by Coherus BioSciences, Inc. expected in early October 2022
AMSTERDAM, the Netherlands, MUNICH, Germany, ZUG, Switzerland, August 03, 2022 / B3C newswire / -- Polpharma Biologics Group BV (“Polpharma Biologics”), Formycon AG (“Formycon”) and Bioeq AG (“Bioeq”), jointly announce that the U.S. Food and Drug Administration (“FDA”) has approved CIMERLI™ (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis® (ranibizumab injection).
FYB201 was developed by Bioeq, a Joint Venture between Polpharma Biologics and Formycon. End of the year 2019, Coherus BioSciences, Inc. (“Coherus”) entered into a license agreement for the exclusive commercialization of FYB201 under the brand name CIMERLI™ in the United States of America (“U.S.”).
CIMERLI™ obtained approval from the FDA for the treatment of Age-Related Neovascular (wet) Macular Degeneration (nAMD) and other serious retinal diseases such as Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema following Retinal Vein Occlusion (RVO) and Myopic Choroidal Neovascularization (mCNV). CIMERLI™ is the first and only interchangeable biosimilar with an exclusivity for 12 months after market launch that is indicated for the treatment of all five Lucentis® indications and, as such, is a new medical option for patients with serious retinal diseases.1
FDA-approval and interchangeability designation are based on a totality of evidence including analytical, nonclinical, clinical and manufacturing data. The efficacy, safety, pharmacokinetics and immunogenicity of CIMERLI™ were found to be comparable to the reference drug Lucentis® in patients with Age-Related Neovascular (wet) Macular Degeneration (nAMD). Clinical readouts from the randomized, double-masked, parallel group, multicenter phase III study (COLUMBUS AMD) have been published in the peer-reviewed journal, Ophthalmology.2
CIMERLI™ belongs to the anti-VEGF therapy class of biologics that have been revolutionary in helping retinal patients in maintaining or regaining vision. It inhibits vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of blood vessels in the retina. The commercial launch of CIMERLI™ in the U.S by Coherus, is planned for early October in both 0.3mg and 0.5mg doses.
AMD is the leading cause of vision loss in adults aged over 60 years old in the U.S., and advanced age-related AMD is the world’s leading cause of irreversible blindness.3 As many as 11 million people in the U.S are living with a form of age-related AMD, a number which is expected to double to nearly 22 million by 2050.3 Due to a projected increase in the incidence of diabetes across the U.S. over the next two decades, the burden of diabetic-related eye diseases, like DME and DR, are also likely to rise.4 As the prevalence of serious retinal diseases increases, so do the costs of treating these diseases. The estimated global cost of visual impairment from AMD is more than $300 billion, including more than $250 billion in direct health care costs.3
“As the impact of serious retinal diseases continues to rise in the U.S., it is critical that treatment options are both efficacious and affordable. Advanced biosimilars to Lucentis® can change patients’ lives, while also minimizing the financial impact of the cost of treatment on healthcare systems,” said Michael Soldan, CEO of Polpharma Biologics Group. “Polpharma Biologics is proud to have collaborated with Formycon and Bioeq on the development of ranibizumab biosimilar and we are excited about our contribution to this valuable treatment option that we expect to positively impact many patients lives.”
“We are very delighted about the full label approval as it will allow to offer this highly effective treatment option to an increasing number of patients with retinal diseases. At the same time, we would like to thank our partners Bioeq and Polpharma Biologics for the excellent joint development work and are pleased that Coherus acts as commercialization partner for the U.S.,” explained Dr. Stefan Glombitza, CEO of Formycon AG.
* CIMERLI™ is a trademark of Coherus BioSciences, Inc.
** Lucentis® is a registered trademark of Genentech Inc.
About Polpharma Biologics
Polpharma Biologics is an international biotechnology company with integrated operations in the European Union (EU), developing and manufacturing biosimilar medicines. Using state-of-the-art platform technologies, Polpharma Biologics develops biosimilar products to treat a range of conditions in major therapeutic areas. Programs at Polpharma Biologics start in cell line development and transition through technical and clinical development to commercial-scale production, preparing drugs for future commercial partnerships with global pharmaceutical organizations. The company pipeline contains more than six biosimilars in different stages of development, including PB006 (biosimilar natalizumab) recently accepted for review by the European Medicines Agency (EMA) and FDA.
Formycon (ISIN: DE000A1EWVY8 / WKN: A1EWVY) is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. Formycon currently has four biosimilars in development. Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 drug FYB207.
Bioeq is a Swiss biopharmaceutical joint venture between Formycon AG and Polpharma Biologics Group BV. Bioeq develops, licenses and commercializes biosimilars.
About Coherus BioSciences
Coherus is a commercial stage biopharmaceutical company building a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business. In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody, in the United States (U.S.) and Canada. A biologics license application for toripalimab for the treatment of nasopharyngeal carcinoma is under review by the FDA with a target action date of December 23, 2022. Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta® in the U.S., and expects to launch CIMERLI™ (ranibizumab-eqrn) in the U.S. in early in October 2022, as well as the FDA-approved Humira® biosimilar YUSIMRY™ (adalimumab-aqvh) in the U.S. in 2023.
Since their introduction in the 1980s, biopharmaceuticals have revolutionized the treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis, multiple sclerosis and eye diseases. In the coming years, many of these biotech drugs will lose their patent protection – and by 2020, medications with revenues of approximately USD 100 billion will be off patent. Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, U.S., Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product. Global sales of biosimilars are estimated to exceed $15 billion by 2020. By 2030, analysts estimate that this figure could rise to over $60 billion.
This press release is issued from Polpharma Biologics Group BV. Although Polpharma Biologics Group BV is not a public company as of this date, recipients should understand that this press release contains certain forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995) relating to the potential benefits, safety and efficacy of CIMERLI™; the timing and status of regulatory filings; risks and uncertainties associated with development and commercialization of drug products; plans, strategies and benefits related to cooperation between the entities named herein; projected increase in the incidence of certain diseases and associated potential costs for healthcare, as well as anticipated global sales of biosimilars. Recipients are cautioned that all forward-looking statements involve risks and uncertainties, including, but not limited to, the statements made in this press release.
Director, Ruder Finn
+44 7788 191434
1 U.S. Food and Drug Administration (FDA) website. Available from: https://www.fda.gov/ (Accessed August 2022)
2 Science Direct: Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration - ScienceDirect
3 BrightFocus Foundation. Available from: Age-Related Macular Degeneration: Facts & Figures | BrightFocus Foundation (Accessed July 2022)
4 Holekamp, NM. Supplements and Featured Publications, Improving Outcomes in Diabetic Macular Edema: The Impact of New Therapies in Managed Care. The American Journal of Managed Care. Volume 22, Issue 10. 2016.
Keywords: Humans; Ranibizumab; Macular Edema; Vascular Endothelial Growth Factor A; Diabetic Retinopathy; Retinal Vein Occlusion; Choroidal Neovascularization; Biosimilar Pharmaceuticals; United States Food and Drug Administration; Wet Macular Degeneration; Retina; Diabetes Mellitus; Blindness; United States
Published by B3C newswire